Navigation Links
Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
Date:3/4/2008

d disease

detection, classification and monitoring of prevalent cancers,

including ovarian, breast and prostate. Vermillion will have access to

exclusive commercial rights to the discoveries made through the

partnership.

-- Vermillion's stockholders and board of directors approved a 1 for 10

reverse stock split of the Company's common stock. The reverse split

became effective at the close of trading on Monday, March 3, 2008.

-- The Ohio State University commercially launched Vermillion's diagnostic

test for managing patients with TTP, a hematological disease. The test

helps physicians make the correct diagnosis, initiate timely treatment,

evaluate response to therapy and predict the risk of recurrence in

patients with TTP.

-- Received issuance of U.S. Patent No. 7,297,556 for aiding diagnosis of

nephrotic syndrome, a kidney disorder marked by very high or low levels

of protein in the urine, which results in bodily swelling and high

cholesterol.

2008 Milestones

The Company's primary goal for 2008 will be to commercialize its diagnostic tests through collaborations with Quest Diagnostics and other thought leaders in oncology, cardiology and hematology. Vermillion expects to attain the following milestones:

-- Present data from three studies highlighting progress in Vermillion's

ovarian cancer diagnostic program at the Society for Gynecologic

Oncologists' (SGO) 2008 Annual Meeting on Women's Cancer held

March 9-12 in Tampa, Florida.

-- Report top-line data from the ovarian tumor triage clinical trial later

this quarter and submit to the U.S. Food and Drug Administration (FDA)

for clearance as an in vitro diagnostic test in the first half of 2008.

-- Work with Quest Diagnostics to integrate Vermillion's PAD proteomic

biomarkers as a laboratory
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
10. Access Highlighted in Recent BusinessWeek Article
11. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... SuperGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... V. McCullar, Ph.D., Vice President of Drug,Discovery Operations, ... Investor Summit on Monday, September 15, 2008 at ...
... Data to be Presented at the 7th International ... Symposium on Uveitis ... a leading,developer of antibody fragment therapeutics, today announced that the,company ... lead product candidate, ESBA105, in ophthalmic indications. In,April 2008, ESBATech ...
... PRICING AVAILABLE ... ANYWHERE ... DEMOfall 08 conference here in San Diego, the launch of the,Familybuilder ... $59.95 DNA tests,the most affordable DNA testing available anywhere., At ...
Cached Biology Technology:SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 3
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... 24, 2013 For the first time, scientists at ... moderate-severe traumatic brain injury (TBI), atrophy (shrinkage) in the ... increased physical, social and cognitive stimulation. The ... in the chronic stages of traumatic brain injury," was ...
... (Sept. 24, 2013) Retinal (or fundus) photography is ... cameras can cost tens to hundreds of thousands of ... ophthalmic practices and to physicians in third-world countries. In ... Ear researchers describe the relatively simple technique of fundus ...
... researchers have identified and validated two rare gene mutations that ... that strikes after the age of 60. The two mutations ... enzyme involved in processing the amyloid precursor protein which ... the fifth AD gene overall. In their ...
Cached Biology News:Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 2Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 3Researchers use smart phone photography to diagnose eye disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 3
... DNA-binding protein(DBP). Protein size: ... NP_001343 ELISA titre using peptide based ... for Western Blot: 1.0g/ml in ... HRP conjugated anti-Rabbit IgG should be diluted ...
Porcine Serum US Origin 6 Months or Older...
... DCTD_HUMAN GI Number: 4503277 ... 20016 Description: FUNCTION: Supplies the ... ACTIVITY: dCMP + H 2 O ... SUBUNIT: Homohexamer. SIMILARITY: Belongs to the ...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: